PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 152 filers reported holding PROGENICS PHARMACEUTICALS IN in Q4 2018. The put-call ratio across all filers is 1.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $248,000 | -90.7% | 65,327 | -87.5% | 0.00% | – |
| Q4 2019 | $2,670,000 | +123.4% | 524,670 | +122.1% | 0.00% | – |
| Q3 2019 | $1,195,000 | -48.3% | 236,280 | -36.9% | 0.00% | – |
| Q2 2019 | $2,310,000 | -28.5% | 374,505 | -46.3% | 0.00% | -100.0% |
| Q1 2019 | $3,233,000 | +424.8% | 696,808 | +374.1% | 0.00% | – |
| Q4 2018 | $616,000 | -57.2% | 146,969 | -35.9% | 0.00% | – |
| Q3 2018 | $1,438,000 | -35.5% | 229,181 | -17.3% | 0.00% | – |
| Q2 2018 | $2,229,000 | -24.4% | 277,171 | -29.9% | 0.00% | -100.0% |
| Q1 2018 | $2,949,000 | +96.5% | 395,270 | +56.6% | 0.00% | – |
| Q4 2017 | $1,501,000 | -65.0% | 252,486 | -56.7% | 0.00% | -100.0% |
| Q3 2017 | $4,292,000 | +54.3% | 583,184 | +42.4% | 0.00% | 0.0% |
| Q2 2017 | $2,781,000 | -23.1% | 409,595 | +6.9% | 0.00% | 0.0% |
| Q1 2017 | $3,617,000 | +39.0% | 383,180 | +27.2% | 0.00% | 0.0% |
| Q4 2016 | $2,603,000 | +3967.2% | 301,328 | +2917.8% | 0.00% | – |
| Q3 2016 | $64,000 | -12.3% | 9,985 | -41.7% | 0.00% | – |
| Q2 2016 | $73,000 | +135.5% | 17,138 | +144.8% | 0.00% | – |
| Q1 2016 | $31,000 | -74.6% | 7,000 | -64.7% | 0.00% | – |
| Q4 2015 | $122,000 | -19.7% | 19,825 | -25.6% | 0.00% | – |
| Q3 2015 | $152,000 | -80.9% | 26,662 | -75.0% | 0.00% | – |
| Q2 2015 | $797,000 | +328.5% | 106,796 | +244.3% | 0.00% | – |
| Q1 2015 | $186,000 | -42.8% | 31,016 | -27.6% | 0.00% | – |
| Q4 2014 | $325,000 | -6.6% | 42,860 | -36.2% | 0.00% | – |
| Q3 2014 | $348,000 | -31.0% | 67,178 | -42.4% | 0.00% | – |
| Q2 2014 | $504,000 | -9.0% | 116,723 | -14.0% | 0.00% | – |
| Q1 2014 | $554,000 | -30.0% | 135,667 | -8.7% | 0.00% | – |
| Q4 2013 | $791,000 | +37.1% | 148,517 | +29.2% | 0.00% | – |
| Q3 2013 | $577,000 | +16.1% | 114,974 | +3.3% | 0.00% | – |
| Q2 2013 | $497,000 | – | 111,306 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|